Stockreport

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting [Yahoo! Finance]

Sonnet BioTherapeutics Holdings, Inc.  (SONN) 
PDF company developing innovative targeted biologic drugs, announced today that preclinical data and clinical trial design from the study of SON-080 (recombinant human Inter [Read more]